Acetazolamide-loaded intravitreal implants for the treatment of glaucoma: formulation, physicochemical characterization and assessment of in vitro and in vivo safety.

Glaucoma is a leading cause of permanent blindness, currently affecting over 75 million individuals worldwide. Treatments primarily aim to lower intraocular pressure (IOP), with acetazolamide being a common pharmacotherapy. However, systemic side effects and poor bioavailability limit its clinical effectiveness.

Nano- and meso-scale aggregation of poly(N-isopropylacrylamide) below the lower critical solution temperature: A wide-angle dynamic light scattering study.

Poly-N-isopropylacrylamide (PNIPAm), a thermorresponsive polymer, highly soluble in water below its lower critical solution temperature (LCST), is widely used in biomedical applications like drug delivery. Being able to measure PNIPAm size and aggregation state in solution quickly, inexpensively, and accurately below the LCST is critical when stoichiometric particle or molecular ratios are required. Dynamic light scattering (DLS) is probably the most widely available, and inexpensive nanoparticle sizing technique, but there are limitations with respect to sample polydispersity.

Ocular pharmacokinetics of acetazolamide from intravitreal implants by high-performance liquid chromatography coupled to tandem mass spectrometry.

Glaucoma, a leading cause of irreversible blindness, affects about 70 million people globally. Its treatment focuses on reducing intraocular pressure. Acetazolamide, a potent anti-glaucoma drug, is currently used only systemically due to low solubility and permeation, which cause severe side effects.

Young-Onset Alzheimer Dementia Due to a Novel Pathogenic Variant Initially Misdiagnosed as Autoimmune Encephalitis.

Objectives: Pathogenic variants in presenilin 1 are related to early-onset Alzheimer disease (AD) and may occur as de novo variants. In comparison with sporadic forms, it can present with psychiatric manifestations, seizures, myoclonus, and focal presentation. Because PSEN1 can occur in young patients who lack a family history of neurologic disorders and because these symptoms are also frequent in autoimmune encephalitis (AE), diagnosis may be overlooked.